- Patient enrollment is underway in a Europe-base study, called OPTIMIZE, evaluating the safety and effectiveness of Cardiovascular Systems' (CSII +3%) orbital artherectomy system with adjunctive drug-coated balloon (DCB) angioplasty compared to DCB angioplasty alone for the treatment of peripheral artery disease (PAD). The study will be specific to PAD patients with calcified below-the-knee (BTK) lesions, typically associated with a higher level of calcium than above-the-knee lesions.
- OPTIMIZE will enroll up to 50 participants across 10 sites in the EU.